Literature DB >> 64868

Success and problems of long-term levodopa therapy in Parkinson's disease.

C D Marsden, J D Parkes.   

Abstract

The patient with Parkinson' disease on chronic levodopa therapy, like the diabetic on insulin, is dependent on the drug. Like the diabetic, the patients with Parkinson's disease may run into problems during long-term treatment. Two have emerged as frequent and serious, an insidious and progressive loss of benefit and the appearance of progessively more severe fluctuations in disability. It is concluded that progression of the underlying pathology of the disease is probably responsible. Discovery of the exact causes for loss of benefit may provide a rational basis for new therapy.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 64868     DOI: 10.1016/s0140-6736(77)91146-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  96 in total

1.  Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase enhance dopamine delivery after L-3, 4-dihydroxyphenylalanine administration in Parkinsonian rats.

Authors:  W Y Lee; J W Chang; N L Nemeth; U J Kang
Journal:  J Neurosci       Date:  1999-04-15       Impact factor: 6.167

2.  Cognitive outcome after unilateral pallidal stimulation in Parkinson's disease.

Authors:  G Vingerhoets; C van der Linden; E Lannoo; V Vandewalle; J Caemaert; M Wolters; D Van den Abbeele
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-03       Impact factor: 10.154

Review 3.  Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management.

Authors:  Teus van Laar
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 4.  Parkinson's disease.

Authors:  C D Marsden
Journal:  Postgrad Med J       Date:  1992-07       Impact factor: 2.401

5.  Cortical regulation of striatal medium spiny neuron dendritic remodeling in parkinsonism: modulation of glutamate release reverses dopamine depletion-induced dendritic spine loss.

Authors:  Bonnie G Garcia; M Diana Neely; Ariel Y Deutch
Journal:  Cereb Cortex       Date:  2010-01-29       Impact factor: 5.357

6.  Therapeutic options for continuous dopaminergic stimulation in Parkinson's disease.

Authors:  O K Sujith; Carol Lane
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

Review 7.  Motor Complications of Dopaminergic Medications in Parkinson's Disease.

Authors:  Maria Eliza Freitas; Christopher W Hess; Susan H Fox
Journal:  Semin Neurol       Date:  2017-05-16       Impact factor: 3.420

Review 8.  Parkinson's disease in 1984: an update.

Authors:  A E Lang; R D Blair
Journal:  Can Med Assoc J       Date:  1984-11-01       Impact factor: 8.262

Review 9.  Therapeutic potential of targeting glutamate receptors in Parkinson's disease.

Authors:  Clare Finlay; Susan Duty
Journal:  J Neural Transm (Vienna)       Date:  2014-02-21       Impact factor: 3.575

10.  Dopaminergic modulation of motor coordinaton in Parkinson's disease.

Authors:  Jaebum Park; Mechelle M Lewis; Xuemei Huang; Mark L Latash
Journal:  Parkinsonism Relat Disord       Date:  2013-09-22       Impact factor: 4.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.